ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback